Surgical Conditions During Laparoscopic Bariatric Surgery
Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Mar 8, 2016
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
Subjects will be randomized to one of four groups:
1. moderate neuromuscular block (NMB) + 10 mm insufflation pressure (IP);
2. moderate NMB + 15 mm IP;
3. deep NMB + 10 mm IP; or
4. deep NMB + 15 mm IP.
A moderate NMB block will be defined as 2-3 twitches in the train of four (TOF) and a deep NMB will be defined as 0-1 posttetanic count. The surgeons will be asked to rate their satisfaction with the surgical conditions using a five-point ordinal scale ranging from 1 (extremely poor) to 5 (optimal conditions). The first rating will occur at the beginning of the procedure when the NMB leve...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • ASA I-III
- • BMI ≥ 35
- Exclusion Criteria:
- • Inability to obtain written informed consent
- • Pregnancy or breastfeeding
- • Allergy to rocuronium, sugammadex, or any anesthetic agents used in the protocol
- • Known or suspected neuromuscular disorders
- • Significant renal disease with a serum creatinine ≥ 2 mg/dl f. Significant liver disease g. A family history of malignant hyperthermia
About University Of Missouri Columbia
The University of Missouri-Columbia is a leading academic institution dedicated to advancing medical research and clinical innovation. As a prominent sponsor of clinical trials, the university leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving patient outcomes across a variety of health conditions. With a commitment to ethical research practices and collaboration with multidisciplinary teams, the University of Missouri-Columbia strives to translate scientific discoveries into effective therapeutic interventions, ultimately enhancing the quality of care in the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbia, Missouri, United States
Patients applied
Trial Officials
Terri G Monk, MD
Principal Investigator
University of Missouri-Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials